Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder

Mt Sinai J Med. 2009 Apr;76(2):198-203. doi: 10.1002/msj.20096.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / epidemiology
  • Canada
  • Cardiovascular System / drug effects*
  • Central Nervous System Stimulants / administration & dosage*
  • Central Nervous System Stimulants / adverse effects
  • Child
  • Child, Preschool
  • Death, Sudden, Cardiac / etiology
  • Death, Sudden, Cardiac / prevention & control*
  • Electrocardiography
  • Humans
  • Mass Screening
  • Practice Guidelines as Topic
  • Product Surveillance, Postmarketing
  • Risk Factors
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Central Nervous System Stimulants